Interleukin-6: A multifunctional targetable cytokine in human prostate cancer

Molecular and Cellular Endocrinology

Volumn 360, Issue 1-2, 2012, Pages 52-58

  Culig, Zoran ^a   Puhr, Martin ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen receptor; Apoptosis; Interleukin 6; Prostate cancer; SOCS; Therapy

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SILTUXIMAB; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN;

ABLATION THERAPY; ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER TISSUE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DRUG MECHANISM; EARLY CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HORMONE ACTION; HUMAN; LONG TERM CARE; METASTASIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE METASTASIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84864017887     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.033     Document Type: Review

References (72)

1. Adler H.L., McCurdy M.A., Kattan M.W., TImme T.L., Scardino P.T., Thompson T.C. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J. Urol. 1999, 161:182-187.
2. Alexander W.S., Hilton D.J. The role of suppressors of cytokine signalling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 2004, 22:503-529.
3. Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S., Myung J.K., Watt K., Tam T., Yang Y.C., Banuelos C.A., Williams D.E., McEvan I.J., Wang Y., Sadar M.D. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010, 17:535-536.
4. Bellezza I., Neuwirt H., Nemes C., Cavarretta I.T., Puhr M., Steiner H., Minelli A., Bartsch G., Offner F., Hobisch A., Doppler W., Culig Z. Suppressor of cytokine signalling-3 antagonizes camp effects on proliferation and apoptosis and is expressed in human prostate cancer. Am. J. Pathol. 2006, 169:2199-2208.
5. Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E. Suppressors of cytokine siignaling (SOCS)1 and SOCS3 interact with and modulate fibroblast growth factor receptor signalling. J. Cell Sci. 2006, 119:380-387.
6. Borowsky A.D., Dingley K.H., Ubick E., Turteltaub K.W., Cardiff R.D., Devere-White R. Inflammation and atrophy precede prostate neoplasia in PhIP-induced rat model. Neoplasia 2006, 8:708-715.
7. Burke W.M., Jin X., Lin H.J., Huang M., Liu R., Reynolds R.K., Lin J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20:7925-7934.
8. Cavarretta I.T., Neuwirt H., Untergasser G., Moser P.L., Zaki M.H., Steiner H., Rumpold H., Fuchs D., Hobisch A., Nemeth J.A., Culig Z. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007, 26:2822-2832.
9. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
10. Chun J.Y., Nadiminty N., Dutt S., Lou W., Yang J.C., Kung H.J., Evans C.P., Gao A.C. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin. Cancer Res. 2009, 15:4815-4822.
11. Chung T.D., Yu J.J., Kong T.A., Spiotto M.T., Lin J.M. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000, 42:1-7.
12. Debes J.D., Schmidt L.J., Huang H., Tindall D.J. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 2002, 62:5632-5636.
13. Debes J.D., Comuzzi B., Schmidt L.J., Dehm S.M., Culig Z., Tindall D.J. P300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res. 2005, 65:5965-5973.
14. Degeorges A., Tatoud R., Fauvel-Lafeve F., Podgornik M.P., Millot G., de Cremous P., Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int. J. Cancer 1996, 68:207-214.
15. Desai S.J., Ma A.H., Tepper C.G., Chen H.W., Kung H.J. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res. 2006, 66:10449-10459.
16. Domingo-Domenech J., Oliva C., Rovira A., Codony-Servat J., Bosch M., Filella X., Montagut C., Tapia M., Campas C., Dang L., Rolfe M., Ross J.S., Gascon P., Albanell J., Mellado B. Interleukin 6, a nuclear factor-kappa B target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor kappa B inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 2006, 12:5578-5586.
17. Dorff T.B., Goldman B., Pinski J.K., Mack P.C., Lara P.N., Van Veldhuizen P.J., Quinn D.I., Vogelzang N.J., Thompson I.M., Hussain M.H. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 Isiltuximab, a monoclonal antibody against IL-6, in patients with castration-resistant prostate cancer. Clin. Cancer Res. 2010, 16:3028-3034.
18. Evans M.K., Yu C.R., Lohani A., Mahdi R.M., Liu X., Trzeciak A.R., Egwuagu C.E. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 2007, 26:1941-1948.
19. Garrett K.P., Aso T., Bradsher J.N., Foundling S.I., Lane W.S., Conaway R.C., Conaway J.W. Positive regulation of general transcription factor SIII by a taiedubiquitin homolog. Proc. Natl. Acad. Sci. USA 1995, 92:7172-7176.
20. Ghosh P.M., Malik S.N., Bedolla R.G., Wang Y., Mikhailova M., Prihoda T.J., Troyer D.A., Kreisberg J.I. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr. Relat. Cancer 2005, 12:119-134.
21. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol. 2001, 159:2159-2165.
22. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., Costello J.F., McCormick F., Jablons D.M. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. USA 2003, 100:14133-14138.
23. Hilton D.J. Negative regulators of cytokine signal transduction. Cell. Mol. Life Sci. 1999, 55:1568-1577.
24. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998, 58:4640-4645.
25. Hobisch A., Rogatsch H., Hittmair A., Fuchs D., Bartsch G., Klocker H., Bartsch G., Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol. 2000, 191:239-244.
26. Hobisch A., Ramoner R., Fuchs D., Godoy-Tundidor S., Bartsch G., Klocker H., Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin. Cancer Res. 2001, 7:2941-2948.
27. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 2005, 41:2502-2512.
28. Ishiguro H., Akimoto K., Nagashima Y., Kojima Y., Sasaki T., Ishiguro-Imagawa Y., Nakaigawa N., Ohno S., Kubota Y., Uemura H. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc. Natl. Acad. Sci. USA 2009, 106:16369-16374.
29. Jarrard D.F., Kinoshita H., Shi Y., Sandefur C., Hoff D., Meisner L.F., Chang C., Herman J.G., Isaacs W.B., Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 1998, 58:5310-5314.
30. Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C., Conaway J.W., Nakayama K.I. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004, 18:3055-3065.
31. Keller E.T., Chang C., Ershler W.B. Inhibition of NFkappaB activity through maintenance of IkapaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J. Biol. Chem. 1996, 27:26267-26275.
32. Kim O., Jiang T., Xie Y., Guo Z., Chen H., Qiu Y. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 2004, 23:1838-1844.
33. Komyod W., Böhm M., Metze D., Heinrich P.C., Behrmann I. Constitutive suppressor of cytokine signalling 3 expression confers a growth advantage to a human melanoma cell line. Mol. Cancer Res. 2007, 5:271-281.
34. Krajewska M., Krajewski S., Epsein J.I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J.C. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am. J. Pathol. 1996, 148:1567-1576.
35. Larsen L., Ropke C. Suppressors of cytokine signalling: SOCS. Apmis 2002, 110:833-844.
36. Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., Gao A.C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 2003, 9:370-376.
37. Lee S.O., Chung J.Y., Nadiminty N., Lou W., Gao A.C. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007, 67:764-773.
38. Malinowska K., Neuwirt H., Cavarretta I.T., Bektic J., Steiner H., Dietrich H., Moser P.L., Fuchs D., Hobisch A., Culig Z. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr. Relat. Cancer 2009, 16:155-169.
39. Masuda M., Wakasaki T., Suzuki M., Toh S., Joe A.K., Weinstein I.B. Stat3 orchestrates tumor development and progression: the Achilleś heel of head and neck cancers?. Curr. Cancer Drug Targets 2010, 10:117-126.
40. Masuhiro Y., Kayama K., Fukushima A., Baba K., Soutsu M., Kamiya Y., Gotoh M., Yamaguchi N., Hanazawa S. SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1. J. Biol. Chem. 2008, 283:31575-31583.
41. Mellinghoff I.K., Vivanco I., Kwon A., Tran C., Wongvipat J., Sawyers C.L. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004, 6:517-527.
42. Nakai Y., Nelson W.G., De Marzo A.W. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. 2007, 67:1378-1384.
43. Neuwirt H., Puhr M., Cavarretta I.T., Mitterberger M., Hobisch A., Culig Z. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr. Relat. Cancer 2007, 14:1007-1019.
44. Neuwirt H., Puhr M., Santer F.R., Susani M., Doppler W., Marcias G., Rauch V., Brugger M., Hobisch A., Kenner L., Culig Z. Suppressor of cytokine signalling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am. J. Pathol. 2009, 174:1921-1930.
45. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Wislon T.A., Zhang J.G., Silva A., Asimakis M., Farley A., Nash A.D., Metcalf D., Hilton D.J., Nicola N., Baca M. Suppressor of cytokine signalling-3 preferentially binds to the SHP-2 binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 2000, 97:6493-6498.
46. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
47. Park J.I., Lee M.G., Cho K., Park B.J., Chae K.S., Byun D.S., Ryu B.K., Park Y.K., Chi S.G. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappa B, JNK, and Ras signalling pathways. Oncogene 2003, 22:4314-4332.
48. Patterson S.G., Wei S., Chen X., Sallman D.A., Gilvary D.L., Zhong B., Pow-Sang J., Yeatman T., Djeu J.Y. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006, 25:6113-6122.
49. Pierconti F., Martini M., Pinto F., Cenci T., Capodimonti S., Calarco A., Bassi P.F., Larocca L.M. Epigenetic silencing of SOCS3 identifies a subset of prostate cancers with an aggressive behavior. Prostate 2010, 71:318-325.
50. Puhr M., Santer F.R., Neuwirt H., Susani M., Nemeth J.A., Hobisch A., Kenner L., Culig Z. Down-regulation of suppressor of cytokine signalling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res. 2009, 69:7375-7384.
51. Puhr M., Saner F.R., Neuwirt H., Marcias G., Hobisch A., Culig Z. SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr. Relat. Cancer 2010, 18:525-538.
52. Qiu Y., Robinson D., Pretlow T.G., Kung H.J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'kinase and is involved in interleukin-6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95:3644-3649.
53. Sadar M.D., Gleave M.E. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res. 2000, 60:5825-5831.
54. Santer F., Malinowska K., Culig Z., Cavarretta I.T. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr. Relat. Cancer 2010, 17:241-253.
55. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., Sasaki M., Johnston J.A., Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory regions well as SH2 domain. Genes Cells 1999, 4:339-351.
56. Siddiqui I.A., Asim M., Hafeez B.B., Adhami V.M., Tarapore R.S., Mukhtar H. Green tea polyphonol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 2011, 25:1198-1207.
57. Smith P.C., Keller E.T. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001, 48:47-53.
58. Spiotto M.T., Chung T.D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000, 42:186-195.
59. Starr R., Wilson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., Hilton D.J. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
60. Steiner H., Godoy-Tundidor S., Rogatsch H., Berger A.P., Fuchs D., Comuzzi B., Bartsch G., Hobisch A., Culig Z. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am. J. Pathol. 2003, 162:655-663.
61. Steiner H., Berger A.P., Godoy-Tundidor S., Bjartell A., Lilja H., Bartsch G., Hobisch A., Culig Z. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur. J. Cancer 2004, 40:1066-1072.
62. Steiner H., Cavarretta I.T., Moser P.L., Berger A.P., Bektic J., Dietrich H., Zaki M.H., Nakada M., Hobisch A., Nemeth J.A., Culig Z. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate 2006, 66:1744-1752.
63. Tam N.N., Leav I., Ho S.M. Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am. J. Pathol. 2007, 171:1334-1341.
64. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995, 45:542-549.
65. Ueda T., Mawji N.R., Bruchovsky N., Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 2002, 277:38087-38094.
66. Wallner L., Dai J., Escara-Wilke J., Zhang J., Yao Z., Lu Y., Trikha M., Nemeth J.A., Zaki M.H., Keller E.T. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 2006, 66:3087-3095.
67. Wang Q., Horiatis D., Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int. J. Cancer 2004, 111:508-513.
68. Weber A., Hengge U.R., Bardenheuer W., Tischoff I., Sommerer F., Markwarth A., Dietz A., Wittekind C., Tannapfel A. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 2005, 24:6699-6708.
69. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007, 7:454-465.
70. Yuan T.C., Veeramani S., Lin M.F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer 2007, 14:531-547.
71. Zegarra-Moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002, 62:1008-1013.
72. Zerbini L.F., Wang Y., Cho J.Y., Liebermann T.A. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and Jund D is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res. 2003, 63:2206-2215.